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Abstract
Objective—The study was conducted to determine the association between the use of injectable
progestin contraception (IPC) and risk of infection with Neiserria gonorrhoea (GC), Chlamydia
trachomatis (CT), bacterial vaginosis (BV) and Trichomonas vaginalis (TV) among women in South
Africa.
Methods—From August 1999 through May 2001, 643 HIV-1 negative women were recruited from
family planning clinics in Orange Farm, South Africa. IPC users (NET-EN and DMPA) and non-
hormonal contraception users were recruited in approximately equal numbers. Eligible participants
were seen at enrolment and four follow-up visits over a 12 month period; 567 returned for at least
one follow up visit. Multivariable Poisson regression models with generalized estimating equations
(GEE) were used to compute the incidence rate ratio for infection with GC, CT, BV and TV by use
of NET-EN or DMPA relative to non-use during follow-up.
Results—In multivariable models, the use of DMPA slightly increased the risk of infection with
CT (IRR1.24; 95% CI 0.80–1.94) and GC (IRR 1.30; 95% CI 0.58–2.98), although these associations
were not statistically significant. In contrast, DMPA appeared to be protective for TV (IRR 0.35;
95% CI 0.12–1.01), although this estimate was very imprecise. Use of both DMPA and NET-EN
were associated with a decreased risk of BV.
Conclusions—Use of DMPA among women in this study population was associated with an
increased, but not statistically significant, risk of cervical infection with chlamydia and gonorrhea
and a decreased risk of TV and BV. Given the inconsistencies and limitations of the data describing
an increased risk for CT and GC with IPC use, the potential risk of STIs must be balanced against
the risk of unintended pregnancy and its health consequences, especially in developing countries.
Women opting to use IPC should be counselled to use condoms to protect against STIs and HIV.
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The prevalence of HIV infection in South Africa is among the highest in the world; more than
30% of women attending antenatal clinics are infected with HIV [1]. In addition, other sexually
transmitted infections (STI), such as chlamydial infection and gonorrhea, are very common in
the general population. In one population-based study of young people age 15–24 years in
South Africa, chlamydial infection was over 9% in young women and more than 3% were
infected with gonorrhea [2].
One of the factors thought to increase the risk of STIs in women is the use of hormonal
contraception [3,4]. Use of hormonal contraception is extremely prevalent with more than 100
million women using them worldwide [5]. In South Africa, an estimated 57% of all women
aged 15 to 49 years have used injectable progestin-only contraception (IPC) at some point in
their lives [6]. Depot medroxyprogesterone acetate (DMPA) and noresthisterone oenanthate
(NET-EN) are the two IPCs available in South Africa. Both are available free of charge at
public sector primary health care facilities and are on the South African Essential Drugs List
[7]. DMPA is administered once every 12 weeks while NET-EN is provided every 8 weeks.
Although the active ingredients in the two methods are different, the World Health
Organization’s Medical Eligibility Criteria for Contraceptive Use classifies DMPA and NET-
EN together with the same safety and efficacy profile [8].
The use of IPCs may increase the risk of cervical infection with chlamydia and gonorrhea in
women [3,4,9]. Three prospective studies have been conducted to date to examine the
association between use of IPC and STI acquisition [3,4,9]. Among U.S. family planning clinic
attendees, the use of DMPA increased the risk of cervical infection with gonorrhea and/or
chlamydia [4]. Among sex workers in Kenya, the use of DMPA was associated with an
increased risk of chlamydial infection but not gonorrhea and a decreased risk of bacterial
vaginosis (BV) and Trichomonas vaginalis (TV) [3]. In a large cohort study among family
planning clinic attendees in Uganda, Zimbabwe and Thailand, DMPA was found to increase
the risk of gonorrhea but not chlamydia [9].
Using data from a prospective study designed to examine the association between the use of
IPC and HIV infection, we examined the association between use of two different IPCs (NET-
EN and DMPA) and STI among South African women. To date, the association between NET-
EN and STI infection has not been examined prospectively, despite the widespread use of NET-
EN, particularly among young women in South Africa [7]. In addition, prospective data on the
association between IPC use and STIs, particularly infections with TV and BV, among ‘low-
risk’ populations in sub-Saharan Africa are limited.
2. Materals and methods
From August 1999 through May 2001, HIV-1 negative women were recruited from family
planning clinics in Orange Farm, a large settlement 60 km from Johannesburg. The main
findings from this study have been published elsewhere [10]. Criteria for inclusion in the study
included age 18– 40 years, sexually active (meaning they had sex) in the past 3 months, not
pregnant or planning to become pregnant for 12 months, consenting to HIV testing and other
study procedures, willing to be contacted at home for follow-up, and not using or planning to
use oral contraceptive pills. IPC users (NET-EN and DMPA) and non-hormonal or non-
contraceptive users were recruited in approximately equal numbers. The main study was
approved by the University of the Witwatersrand Research Ethics Committee and the
secondary data analysis for the present study was approved by the University of North Carolina
at Chapel Hill. Informed consent was conducted in the main trial.
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Eligible participants were seen at enrolment and months 2, 6, 8 and 12 (NET-EN users) or
months 3, 6, 9 12 (DMPA users and controls). Participants were interviewed by means of a
structured questionnaire to collect information on demographics, STI/HIV prevention
knowledge and sexual history at enrolment and at all visits on sexual practices, condom use,
and current contraceptive method. At each visit, a pelvic examination was performed, vaginal
specimens were collected, and STIs were treated using the syndromic approach (using standard
algorithms based on signs and symptoms of STIs). STI and HIV testing were performed at
each visit.
2.1. Laboratory methods
Infections with Chlamydia trachomatis (CT) and Neiserria gonorrhoea (NG) were detected
from urine using ligase chain reaction (LCx; Abbot Laboratories) at enrolment and each follow-
up visit. Five mL of clean-catch urine was collected at each study visit, transported daily to the
laboratory, an aliquot tested by LCR for gonorrhea and chlamydia and the remainder frozen at
-70%, and shipped to the CDC for batch testing. Vaginal swabs were cultured in Diamond’s
media for detection of Trichomonas vaginalis (TV). Bacterial vaginosis (BV) was assessed
from a gram stained smear of a vaginal swab using Nugent’s criteria. A score ≥7 was
categorized as positive. A proportion of Gram-stain slides were sent to the CDC in the US for
re-assessment of Nugent’s scoring and diagnosis of BV. All specimens were tested at the
Contract Laboratory Services which is a joint partnership between the National Health
Laboratory Service and the School of Pathology at the University of the Witwatersrand in South
Africa. All laboratory procedures and validations met with CDC approval.
2.2. Statistical analysis
To assess the association between use of IPCs and incident STI infection, we used multivariable
Poisson regression models with generalized estimating equations (GEE) to compute incidence
rate ratios for infection by use of hormonal contraception (HC), relative to non use. Separate
models were constructed for each of the four STIs examined. We defined an incident infection
as the first positive test following a negative test. Therefore, a woman could have multiple
incident infections. For BV, we examined both incident infections and any infection after the
first negative result given the long time between follow-up visits and the relatively high
recurrence of BV, thus a positive BV test following a previous BV; test could well be an incident
case of BV [11].
We examined the use of IPC as a three-part variable coded as: use of DMPA, use of NET-EN
or no HC use. Use of IPC was determined based on self report at each visit. Any visit where
the woman tested positive for pregnancy or HIV was excluded from analysis due to the fact
that pregnancy is more likely amongst those women not using HC [4] and HIV may affect the
risk of STI acquisition [3].
We examined the following variables as potential confounding factors based on a priori
hypotheses: age (15–24 years vs. 25–40 years), relationship status, education (less than high
school vs. greater than high school), frequency of sex in past 3 months (one or more times a
week vs. less than one time a week), number of partners in past 3 months (one vs. more than
one), condom use in past 3 months (always vs. sometimes/never), cleaning inside the vagina
(douching) in past 3 months (yes vs no), and age of first sex (14 or younger vs. older than 14).
For multivariable models, variables were kept in the final model based on a backward
elimination procedure (10% change in effect estimate) and based on a priori hypotheses; age,
education and condom use consistency were forced into the final model. Effect modification
of age on use of IPC was assessed.
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Among women reporting switching contraceptive methods during the study (N=181), we
assessed the effect of a ‘wash-out’ period for switches from NET-EN or DMPA to a non-
hormonal method during the study follow-up period in a sensitivity analysis. We imposed a
lag time which counted the first non-exposed visit as 180 days from the last visit where HC
use was reported [12]. We also conducted an analysis where we excluded all women who
reported switching methods. Point estimates generated from the analysis conducted allowing
for switching and the wash-out period were similar to the main analysis that did not take these
factors into account (data not shown).
3. Results
A total of 567 HIV negative women returned for at least one follow-up visit of 643 enrolled.
At baseline, 4.0% tested positive for GC, 14.0% for CT, 7.8% for TV and 35.6% for BV. In
the study population, 45.3% of women were not using any HC, 19.9% were using DMPA and
34.7% NET-EN at baseline (Table 1). The mean age was 27.7 years. Over one-third (37.3%)
of women reported that they were married and cohabiting at baseline, 38.5% reported that they
had a boyfriend that they were not living with, and 17.7% reported having a boyfriend that
they were living with (Table 1). The majority of women (76.5%) reported having at least a
high school education. Internal vaginal washing (douching) was reported by 43% of women
and of these women, 87% reported douching every time she had sex. Dry sex was not common
in this population, only 3% of women reported using anything to dry their vagina for the purpose
of having dry sex. Any condom use in the past 3 months was reported by 54.6% of women
who had ever used condoms and 79% of women stated that they only had one sex partner in
the past 12 months.
Among the women with at least one follow-up visit, we observed 45 incident infections with
gonorrhea, 119 with chlamydia, and 47 with TV yielding incidence rates of 9.9/100 person-
years, 28.2/100 person-years, and 10.2/100 person-years, respectively, (Table 2). We observed
a higher incidence of BV (n=281 episodes; incidence rate = 93.5/100 person-years) (Table 2).
In multivariable models adjusting for age, education, and condom use consistency in the past
3 months, use of DMPA was associated with a slightly increased risk of infection with
chlamydia (IRR 1.24; 95% CI 0.80–1.94) and gonorrhea (IRR 1.30), the latter observation had
very wide confidence intervals (95% CI 0.58–2.98). In contrast, a protective effect was
observed with DMPA and TV (IRR 0.35; 95% CI 0.12–1.01), although this estimate was
somewhat imprecise. NET-EN use was not clearly associated with CT or GC.
Considering incident infections (defined as a positive test following a negative test), DMPA
and NET-EN were not strongly associated with BV. However, when all instances of BV in
follow-up visits were considered, including those episodes that followed a previous positive
result after the first negative test, both DMPA and NET-EN demonstrated protective effects
(DMPA: incidence rate ratio (IRR) 0.74; 95% CI 0.59–0.93; NET-EN: IRR 0.78; 95% CI 0.64–
0.94).
4. Discussion
We found that use of DMPA in this population of South African family planning clinic
attendees was associated with similar slight increases in risk for chlamydial infection and
gonorrhea, although the associations were not statistically significant. In contrast, DMPA
appeared to be protective for TV, although this estimate was imprecise. Use of both DMPA
and NET-EN were associated with a decreased risk of BV, although these associations were
only statistically significant when considering all cases of BV.
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Three other prospective studies have explored the relationship between use of IPCs and STI
acquisition. In a study of sex workers in Kenya, the use of DMPA was associated with a
significant increased risk of chlamydia but not gonorrhea [3]. Among family planning clinic
attendees in Zimbabwe, Uganda, and Thailand, use of DMPA was associated with an increased
risk of gonorrhea but not chlamydia [9], while use of DMPA increased the risk of cervical
infection with either gonorrhea or chlamydia among family planning clinic attendees in the US
[4]. Only one other study has examined the associated between use of IPC and TV or BV, and
this study found a decreased risk of both with the use of IPC [3].
The observed relationships between IPC and STIs are biologically plausible. Although the
differences in the effects of progestogens (natural progesterone versus synthetic progestins)
are not well defined, progestogens could reduce lactobacilli, thus increasing vaginal pH and
susceptibility to cervical infections [13–15]. They may also depress the immune system,
thereby increasing risk to cervical infections [4]. Progestogens support the growth and
persistence of C trachomatis whereas they may suppress the growth of N gonorrhoeae [16].
A decreased risk of trichomoniasis may be the result of growth inhibition as a result of
“exogenous hormones of estrogen and androgen receptors on T vaginalis” [3,17]. Another
possible causal mechanism for the decreased risk of TV and also for BV may be the result of
amenorrhea, a common side effect of IPC. TV growth has been found to be most predominant
immediately following menses when lactoferrin concentrations are highest and thus iron
availability from lactoferrin is greatest [18]. Increased iron has been found to enhance the
adherence and cytoxoicity of trichomondas [19]. Reduced BV rates could be due to progestin-
induced amenorrhoea; menses have been shown to destabilize the vaginal flora resulting in
high concentrations of non-lactobacillus species that favor BV [20].
From a public health perspective, questions have arisen as to the messages that should be
conveyed to clinicians and users of IPCs with regard to the potential risk of cervical infection
with gonorrhea or chlamydia. There are now four longitudinal, observational studies that have
found an increased risk of cervical infection with either GC or CT among women who use
DMPA. These findings come from different populations that include sex workers in Kenya,
and family planning clinic attendees in the US, South Africa, Zimbabwe, Uganda and Thailand.
Currently, the 2004 WHO Medical Eligibility Criteria states “limited evidence suggests that
there may be an increased risk of chlamydial cervicitis among DMPA users at high risk for
STIs” [8]. For other STIs, they state that there is either no evidence of an association or too
limited evidence to draw any conclusions. Certainly, women using HC, including IPCs, should
continue to be counselled to use condoms to reduce their risk of STIs and HIV. Nevertheless,
given that many women using IPC are likely in long-term relationships and may be using HC
because they cannot use male condoms, the likelihood of using condoms for some women is
slim. Currently, women at high risk of STIs do not need to be discouraged from using IPCs.
Given the inconsistencies and limitations of the data describing an increased risk for CT and
GC with IPC use, the potential risk of STIs must be balanced against the risk of unintended
pregnancy and its health consequences, especially in developing countries.
The main limitation of this and other studies is that residual and unmeasured confounding
related to women who chose to use IPCs may explain the observations. Women using IPCs
are less likely to use condoms and may have other behaviors or characteristics that differ from
women who do not use HC [5]. Although we adjusted for condom use in our analysis,
measurement error with regard to over- or under-reporting of condom use may have resulted
in our inability to adequately adjust for differential use between IPC users and non-users. In
addition, factors such as education, gender power dynamics within relationships, partner
characteristics, condom use self-efficacy, and other factors that are associated with use of IPCs
and STI risk may not be adequately measured or adjusted for.
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Use of DMPA among women in this study population was associated with a slight, but not
significant, increase in the risk of cervical infection with Chlamydia and gonorrhea. A
randomized, controlled trial may be necessary to adequately determine whether IPCs, and other
HC, increase STI and HIV risk. Although the evidence is not conclusive with regard to cervical
infection and use of IPC, women opting to use IPC should be counselled that sex without
condom use may place them at continued risk of STIs and HIV.
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Table 1







Married- cohabiting 211 37.3
Married- not cohabiting 9 1.6
Boyfriend- cohabiting 100 17.7
Boyfriend- not cohabiting 218 38.5
Casual partner 23 4.1
No current partner 5 0.9
Education (n=544)
Less than high school 128 23.5




Frequency of douching in past 3 months
(n=243)
Every time she has sex 212 87.2
Sometimes or never 31 12.8
Used anything to dry vagina for purpose of dry sex in past 3 mo (n=567)
Yes 17 3.0
No 550 97.0
Condom use in last 3 months (n=383)
Yes 209 54.6
No 174 45.4
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Table 3
Unadjusted and adjusted incidence rate ratios and 95% confidence intervals for infection with CT, GC, BV or
TV amongst women ages 18–40 years in Orange Farm, South Africa using IPC (either DMPA or NET-EN)
compared to those women not using hormonal contraception (HC), 1999–2001
Unadjusted IRR Adjusted IRR
CT
No HC use 1.0 1.0
DMPA 1.18 (0.77–1.81) 1.24 (0.80–1.94)
NET-EN 0.93 (0.60–1.43) 0.91 (0.59–1.43)
GC
No HC use 1.0 1.0
DMPA 1.19 (0.53–2.65) 1.30 (0.58–2.98)
NET-EN 1.41 (0.70–2.85) 1.11 (0.55–2.25)
TV
No HC use 1.0 1.0
DMPA 0.38 (0.13–1.08) 0.35 (0.12–1.01)
NET-EN 0.59 (0.28–1.23) 0.63 (0.30–1.29)
BV
No HC use 1. 1.0
DMPA 0.75 (0.55–1.02) 0.77 (0.56–1.06)
NET-EN 0.89 (0.69–1.14) 0.91 (0.70–1.18)
All models adjusted for age, education, and condom use consistency in the past 3 months.
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